1. Academic Validation
  2. Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor

Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor

  • Front Synaptic Neurosci. 2018 Feb 21;10:2. doi: 10.3389/fnsyn.2018.00002.
Lani S Chun 1 Rakesh H Vekariya 2 R Benjamin Free 1 Yun Li 3 Da-Ting Lin 3 Ping Su 4 Fang Liu 4 Yoon Namkung 5 Stephane A Laporte 5 Amy E Moritz 1 Jeffrey Aubé 2 Kevin J Frankowski 2 David R Sibley 1
Affiliations

Affiliations

  • 1 Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States.
  • 2 Department of Medicinal Chemistry and Specialized Chemistry Center, University of Kansas, Lawrence, KS, United States.
  • 3 Neural Engineering Unit, Behavior Neuroscience Research Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, United States.
  • 4 Molecular Neuroscience, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada.
  • 5 Department of Medicine, McGill University Health Center Research Institute, McGill University, Montreal, QC, Canada.
Abstract

The dopamine D2 receptor (D2R) is known to elicit effects through activating two major signaling pathways mediated by either G proteins (Gi/o) or β-arrestins. However, the specific role of each pathway in physiological or therapeutic activities is not known with certainty. One approach to the dissection of these pathways is through the use of drugs that can selectively modulate one pathway vs. the other through a mechanism known as functional selectivity or biased signaling. Our laboratory has previously described a G protein signaling-biased agonist, MLS1547, for the D2R using a variety of in vitro functional assays. To further evaluate the biased signaling activity of this compound, we investigated its ability to promote D2R internalization, a process known to be mediated by β-arrestin. Using multiple cellular systems and techniques, we found that MLS1547 promotes little D2R internalization, which is consistent with its inability to recruit β-arrestin. Importantly, we validated these results in primary striatal neurons where the D2R is most highly expressed suggesting that MLS1547 will exhibit biased signaling activity in vivo. In an effort to optimize and further explore structure-activity relationships (SAR) for this scaffold, we conducted an iterative chemistry campaign to synthesize and characterize novel analogs of MLS1547. The resulting analysis confirmed previously described SAR requirements for G protein-biased agonist activity and, importantly, elucidated new structural features that are critical for agonist efficacy and signaling bias of the MLS1547 scaffold. One of the most important determinants for G protein-biased signaling is the interaction of a hydrophobic moiety of the compound with a defined pocket formed by residues within transmembrane five and extracellular loop two of the D2R. These results shed new LIGHT on the mechanism of biased signaling of the D2R and may lead to improved functionally-selective molecules.

Keywords

D2 dopamine receptor; MLS1547; biased signaling; functional selectivity; quinoline; structure-activity relationship.

Figures
Products